Brent Saunders [Getty Photos]
June 25, 2019 06:51 AM EDTUpdated June 26, 10:32 AM
Deals

Ab­b­Vie seals $63B deal to buy a trou­bled Al­ler­gan — spelling out $1B in R&D cuts

John Carroll

Editor & Founder

Brent Saun­ders has found his way out of the cur­rent fix he’s in at Al­ler­gan $AGN. He’s sell­ing the com­pa­ny to Ab­b­Vie for $63 bil­lion in the lat­est ex­am­ple of the hot M&A mar­ket in bio­phar­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Ex­clu­sive: In $1B+ bet on AI, bio­phar­ma heavy­weights back new start­up to up­end drug R&D

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py R&D fa­cil­i­ty as it elim­i­nates jobs and costs

Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

A service from the Financial Times